Data:
{}
Data:
{}
Data:
{
"volume": null,
"avgVolume": null,
"short_ratio": [
{
"symbol": "ADC",
"file_date": "2026-07-20",
"date": "20260720",
"short_volume": 136076,
"short_exempt_volume": 177,
"total_volume": 242611,
"short_volume_ratio": 0.5609,
"signal": "Bearish"
}
]
}
Data:
{
"revenue_history": []
}
Data:
{
"price": null,
"rsi": null,
"sma50": null,
"sma200": null,
"adx": null,
"high_52w": null,
"low_52w": null,
"structure": {
"ema8": null,
"ema21": null,
"ema50": 76.7965420085612,
"ema200": null,
"checks": {
"price_above_all": false,
"ema_stacked": false,
"ema21_rising": false,
"ema50_rising": true,
"adx_over_30": false,
"higher_highs_lows": null,
"near_21ema": false
},
"dist_21ema_pct": null,
"crossover": {
"fresh_cross": null,
"pre_compressed": null,
"held_above_21": null,
"candles_since": null,
"intraday_support": null
},
"momentum": {},
"relative_strength": {
"sector": "Real Estate",
"sector_etf": "XLRE",
"checks": {
"beats_spy_all": true,
"beats_sector_10d": true,
"rs_line_at_high": true,
"sector_top3": false
}
},
"commodity": {},
"universe": {
"checks": {
"price_over_20": true,
"avg_vol_over_2m": false,
"mcap_over_1b": true,
"no_earnings_7d": true,
"not_lev_etf_spac": true,
"bidask_spread": null,
"dollar_vol_over_10m": true
},
"avg_dollar_vol": 91655532.5,
"avg_vol": 1143550
},
"options": {
"checks": {
"call_vol_2x": false,
"ivr_under_40": true,
"iv_contracting": false,
"oi_calls_above_price": false
},
"vals": {
"call_vol_mult": 0.0,
"iv_rank": 30.0
}
}
}
}
Data:
{
"estimates": {},
"price_target": {},
"ratings": {},
"grades": []
}
Data:
[
{
"title": "Is Pfizer (PFE) Undervalued After IBRANCE Won A New FDA Approval?",
"url": "https://finance.yahoo.com/markets/stocks/articles/pfizer-pfe-undervalued-ibrance-won-151139089.html",
"source": "Yahoo! Finance",
"date": "2026-07-08T15:11:39Z",
"summary": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.\n\nRecent interest in Pfizer (PFE) has been driven by U.S. regulators approving IBRANCE as the first CDK4/6 in"
},
{
"title": "Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?",
"url": "https://finance.yahoo.com/healthcare/articles/genmab-gmab-stock-undervalued-positive-150448785.html",
"source": "Yahoo! Finance",
"date": "2026-07-08T15:04:48Z",
"summary": "We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Genmab A/S (NASDAQ:GMAB) is one of the best healthcare stocks on our list.\n\nTheFly reported on July 2 that H.C. Wainwright analyst Raghuram Selvaraju increased the price target on GMAB to $40 from"
},
{
"title": "6 Monthly Dividend Stocks: The Winners, the Losers, and 1 Standout",
"url": "https://www.investing.com/analysis/the-monthly-dividend-lieand-the-elite-84-payout-thats-true-200683530",
"source": "Investing.com",
"date": "2026-07-08T11:10:00Z",
"summary": "An analysis of six major monthly dividend-paying stocks over a decade reveals mixed results. While some companies like Main Street Capital (MAIN) have consistently paid monthly dividends with strong total returns of 236%, others like EPR Properties and Apple Hospitality suspended"
},
{
"title": "The Monthly Dividend Lie -- and the Elite 8.4% Payout That's True",
"url": "https://www.investing.com/analysis/the-monthly-dividend-lieand-the-elite-84-payout-thats-true-200683530",
"source": "Investing.com",
"date": "2026-07-08T09:33:44Z",
"summary": "In the working world, paychecks show up every two weeks. Or at least, every month. Which keeps up with the pace of monthly bills, charges, and expenses.\n\nIn the stock market world, payouts (dividends!) arrive every quarter. That's 30 days in between bills, but a full 90 days span"
},
{
"title": "Biocytogen and Whitehawk partner to develop ADCs",
"url": "https://finance.yahoo.com/healthcare/articles/biocytogen-whitehawk-partner-develop-adcs-085909634.html",
"source": "Yahoo! Finance",
"date": "2026-07-08T08:59:09Z",
"summary": "Biocytogen and Whitehawk Therapeutics are set to develop bispecific antibody-drug conjugates (BsADCs), as part of a global partnership.\n\nUnder this collaboration, Biocytogen will offer access to up to five bispecific antibodies via its RenLite platform.\n\nWhitehawk Therapeutics wi"
},
{
"title": "Novartis to acquire Myricx Bio in up to $1.5bn deal",
"url": "https://finance.yahoo.com/healthcare/articles/novartis-acquire-myricx-bio-1-110800260.html",
"source": "Yahoo! Finance",
"date": "2026-07-06T11:08:00Z",
"summary": "Novartis has signed an agreement to purchase Myricx Bio, a UK-based biotechnology company, in a transaction valued at up to $1.5bn.\n\nThe deal includes an upfront payment of $1.1bn and up to $400m in potential milestone payments.\n\nIt is expected to close in the second half of 2026"
},
{
"title": "Novartis to Buy Cancer-Drug Firm Myricx for Up to $1.5 Billion",
"url": "https://www.bloomberg.com/news/articles/2026-07-06/novartis-to-buy-cancer-drug-firm-myricx-for-up-to-1-5-billion",
"source": "Bloomberg Business",
"date": "2026-07-06T06:58:44Z",
"summary": "Novartis AG agreed to buy British biotech Myricx Bio for as much as $1.5 billion, adding an experimental cancer drug designed to deliver more potent treatments directly to tumors while limiting damage to healthy cells.\n\nMyricx shareholders will receive $1.1 billion upfront, and a"
},
{
"title": "Inocras, AimedBio team up for cancer treatments",
"url": "https://finance.yahoo.com/healthcare/articles/inocras-aimedbio-team-cancer-treatments-082334058.html",
"source": "Yahoo! Finance",
"date": "2026-07-02T08:23:34Z",
"summary": "US-based precision medicine company Inocras has entered a strategic partnership with South Korean biopharmaceutical company AimedBio to enhance cancer drug development using whole genome intelligence.\n\nThe deal includes a strategic equity investment by AimedBio in Inocras and a j"
},
{
"title": "Guggenheim reiterates Merck stock Buy rating on partner trial data By Investing.com",
"url": "https://www.investing.com/news/analyst-ratings/guggenheim-reiterates-merck-stock-buy-rating-on-partner-trial-data-93CH-4795506",
"source": "Investing.com",
"date": "2026-04-20T18:08:21Z",
"summary": "Investing.com - Guggenheim reiterated a Buy rating and $145.00 price target on Merck (NYSE:MRK) following positive Phase 3 trial results from partner Kelun-Biotech. The stock currently trades at $123.61, and InvestingPro analysis suggests the company is undervalued, with shares u"
},
{
"title": "GSK completes $10.6 billion acquisition of Nuvalent By Investing.com",
"url": "https://www.investing.com/news/company-news/gsk-completes-106-billion-acquisition-of-nuvalent-93CH-4793411",
"source": "Investing.com",
"date": "2026-04-20T18:08:21Z",
"summary": "LONDON - GSK plc (LSE/NYSE:GSK) announced today the completion of its acquisition of Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company based in Boston focused on oncology therapies, according to a press release statement.\n\nThe transaction has an aggregate e"
},
{
"title": "Top REITs to Watch: BofA Analyst Names Seven Best Picks By Investing.com",
"url": "https://www.investing.com/news/stock-market-news/top-reits-to-watch-bofa-analyst-names-seven-best-picks-93CH-4789512",
"source": "Investing.com",
"date": "2026-04-20T18:08:21Z",
"summary": "Investing.com -- Bank of America analyst Jeffrey Spector has identified seven top real estate investment trusts across multiple property sectors in his latest weekly research note. The selections come as REITs trade at 92% of BofA's net asset value versus a long-term average of 9"
},
{
"title": "Why is Sichuan Kelun Biotech stock sliding today? By Investing.com",
"url": "https://www.investing.com/news/stock-market-news/why-is-sichuan-kelun-biotech-stock-sliding-today-93CH-4780681",
"source": "Investing.com",
"date": "2026-04-20T18:08:21Z",
"summary": "Investing.com -- Sichuan Kelun Biotech stock fell 8.2% to HK$471.8 on Wednesday after the company disclosed a large pre-market share placement at a steep discount to its previous close.\n\nThe company entered into a placement agreement before the opening bell on July 8, pricing app"
},
{
"title": "VERAXA Biotech targets 2028 IND filing for lead candidate By Investing.com",
"url": "https://www.investing.com/news/company-news/veraxa-biotech-targets-2028-ind-filing-for-lead-candidate-93CH-4776162",
"source": "Investing.com",
"date": "2026-04-20T18:08:21Z",
"summary": "ZURICH - VERAXA Biotech AG (NASDAQ:VRXA) announced plans to advance its BiTAC-based T cell engager VXA-102 to IND/CTA-ready status by early 2028, according to a press release statement issued today. The strategic announcement comes as the biotech company, valued at a market capit"
},
{
"title": "Novartis to acquire Myricx Bio for $1.1bn to expand cancer drugs By Investing.com",
"url": "https://www.investing.com/news/stock-market-news/novartis-to-acquire-myricx-bio-for-11bn-to-expand-cancer-drugs-93CH-4775851",
"source": "Investing.com",
"date": "2026-04-20T18:08:21Z",
"summary": "Investing.com -- Novartis announced today that it has entered into an agreement to acquire Myricx Bio, a privately held UK-based biotechnology company, for $1.1 billion upfront with up to $400 million in potential milestone payments.\n\nThe acquisition adds a potential first-in-cla"
},
{
"title": "Immunome director Barchas sells $4.39m in common stock By Investing.com",
"url": "https://www.investing.com/news/insider-trading-news/immunome-director-barchas-sells-439m-in-common-stock-93CH-4774898",
"source": "Investing.com",
"date": "2026-04-20T18:08:21Z",
"summary": "Isaac Barchas, a director at Immunome Inc. (NASDAQ:IMNM), indirectly sold common stock totaling $4,393,024 across multiple transactions on June 30 and July 2, 2026. The sales occurred within a price range of $21.12 to $23.33 per share. The timing of these sales comes after a rema"
},
{
"title": "Veraxa initiates cell line development for lead cancer therapy By Investing.com",
"url": "https://www.investing.com/news/company-news/veraxa-initiates-cell-line-development-for-lead-cancer-therapy-93CH-4772813",
"source": "Investing.com",
"date": "2026-04-20T18:08:21Z",
"summary": "ZURICH - Veraxa Biotech AG (NASDAQ:VRXA) announced today the initiation of cell line development for its lead BiTAC T-cell engager program, according to a press release statement. The announcement comes as the biotech company, valued at a market capitalization of $43.5 million, t"
},
{
"title": "Engineers Gate Builds $85 Million Position in Net-Lease Retail REIT Agree Realty",
"url": "https://www.fool.com/coverage/filings/2026/03/12/engineers-gate-builds-usd85-million-position-in-net-lease-retail-reit-agree-realty/?source=iedfolrf0000001",
"source": "The Motley Fool",
"date": "2026-03-12T21:20:51Z",
"summary": "Engineers Gate Manager LP increased its stake in Agree Realty (ADC) by 1,144,617 shares, bringing its total position to $85.16 million. The investment represents 1.01% of the fund's assets under management. ADC shares have appreciated 13.4% over the past year, outperforming the S"
},
{
"title": "Where Will Realty Income Stock Be in 1 Year?",
"url": "https://www.fool.com/investing/2026/02/21/where-will-realty-income-stock-be-in-1-year/?source=iedfolrf0000001",
"source": "The Motley Fool",
"date": "2026-02-22T03:05:00Z",
"summary": "Realty Income, the largest net lease REIT with 15,500 properties, faces growth challenges due to its massive size. The company is diversifying by expanding into Europe and Mexico, and building a new institutional asset management business to create a new growth engine. The succes"
},
{
"title": "2 REITs with \u2019Mafioso\u2019 Economics Yielding Up to 5.2%",
"url": "https://www.investing.com/analysis/2-reits-with-mafioso-economics-yielding-up-to-52-200674846",
"source": "Investing.com",
"date": "2026-02-11T13:33:00Z",
"summary": "The article highlights two net-lease REITs as attractive income investments in a lower interest rate environment. W.P. Carey (WPC) and Agree Realty (ADC) offer yields of 5.2% and 4.2% respectively, with strong fundamentals including high occupancy rates, quality tenants, and grow"
},
{
"title": "3 Stocks That Cut You a Check Each Month",
"url": "https://www.fool.com/investing/2026/01/06/3-stocks-that-cut-you-a-check-each-month/?source=iedfolrf0000001",
"source": "The Motley Fool",
"date": "2026-01-06T21:15:00Z",
"summary": "The article highlights three monthly dividend-paying REITs suitable for different investor profiles: Realty Income offers a conservative 5.6% yield with 30 years of annual dividend increases; Agree Realty provides faster growth at 4.3% yield with 6% annualized dividend growth; an"
},
{
"title": "Best Stock to Buy Right Now: Costco vs. Agree",
"url": "https://www.fool.com/investing/2025/10/26/best-stock-to-buy-right-now-costco-vs-agree/?source=iedfolrf0000001",
"source": "The Motley Fool",
"date": "2025-10-26T08:25:00Z",
"summary": "The article compares Costco, a club store retailer, and Agree Realty, a retail property REIT, analyzing their growth potential, valuation, and dividend yields. While both are performing well, Agree Realty appears to offer a more attractive investment option with a higher dividend"
},
{
"title": "Meet the Little-Known Company Yielding 4.2% That Continues to Deliver Monthly for Income Seekers and Is Making Patient Investors Notably Richer",
"url": "https://www.fool.com/investing/2025/10/15/meet-the-little-known-company-yielding-42-that-con/?source=iedfolrf0000001",
"source": "The Motley Fool",
"date": "2025-10-15T11:35:00Z",
"summary": "Agree Realty, a REIT owning over 2,500 retail properties across the US, offers a stable 4.2% monthly dividend by leasing to financially strong retailers like Walmart, Tractor Supply, and Dollar General. The company has a conservative investment strategy focusing on resilient reta"
},
{
"title": "10 Dividend Stocks to Hold for the Next 10 Years",
"url": "https://www.fool.com/investing/2025/09/09/10-dividend-stocks-to-hold-for-the-next-10-years/?source=iedfolrf0000001",
"source": "The Motley Fool",
"date": "2025-09-09T09:10:00Z",
"summary": "The article highlights 10 dividend stocks with strong track records, consistent dividend payments, and potential for long-term growth across various sectors like retail, finance, and consumer goods."
},
{
"title": "Best Stock to Buy Right Now: Realty Income vs. Agree Realty",
"url": "https://www.fool.com/investing/2025/08/22/best-stock-to-buy-right-now-realty-income-vs-agree/?source=iedfolrf0000001",
"source": "The Motley Fool",
"date": "2025-08-22T08:05:00Z",
"summary": "Two leading net lease REITs, Realty Income and Agree Realty, offer different investment profiles. Realty Income provides diversification and reliable income, while Agree Realty presents stronger growth potential in the retail property market."
},
{
"title": "2 Stocks That Cut You a Check Each Month",
"url": "https://www.fool.com/investing/2025/08/07/2-stocks-that-cut-you-a-check-each-month/?source=iedfolrf0000001",
"source": "The Motley Fool",
"date": "2025-08-07T09:35:00Z",
"summary": "Two net lease real estate investment trusts (REITs), Realty Income and Agree Realty, offer attractive monthly dividend options for investors seeking consistent income, with each providing unique advantages in the retail property market."
}
]
Data:
{}
Data:
{
"borrow": [
{
"date": "2026-07-20",
"fee_pct": 0.2851,
"available": 1400000,
"rebate_pct": 3.3349,
"high_fee": 0.4081,
"low_fee": 0.2851,
"utilization_signal": "Low"
},
{
"date": "2026-07-17",
"fee_pct": 0.4081,
"available": 1400000,
"rebate_pct": 3.2119,
"high_fee": 0.419,
"low_fee": 0.4081,
"utilization_signal": "Medium"
},
{
"date": "2026-07-16",
"fee_pct": 0.419,
"available": 1500000,
"rebate_pct": 3.2111,
"high_fee": 0.419,
"low_fee": 0.419,
"utilization_signal": "Medium"
},
{
"date": "2026-07-15",
"fee_pct": 0.419,
"available": 1400000,
"rebate_pct": 3.2111,
"high_fee": 0.419,
"low_fee": 0.312,
"utilization_signal": "Medium"
},
{
"date": "2026-07-14",
"fee_pct": 0.312,
"available": 1400000,
"rebate_pct": 3.308,
"high_fee": 0.312,
"low_fee": 0.3102,
"utilization_signal": "Medium"
}
],
"short_interest": [
{
"symbol": "ADC",
"file_date": "",
"error": "Symbol not found in FINRA biweekly file"
}
],
"ftd": {
"symbol": "ADC",
"periods": [
{
"file_period": "202603b",
"settlement_date": "20260331",
"quantity_fails": 3916,
"price": 74.97
},
{
"file_period": "202604a",
"settlement_date": "20260406",
"quantity_fails": 19,
"price": 76.61
},
{
"file_period": "202604b",
"settlement_date": "20260429",
"quantity_fails": 801,
"price": 76.85
},
{
"file_period": "202606b",
"settlement_date": "20260630",
"quantity_fails": 6,
"price": 76.93
}
],
"trend": "falling",
"trend_description": "FTD quantity declining \u2014 shorts covering or delivery improving"
}
}
Data:
{
"insider": [],
"congress": [],
"dark_pool": [
{
"ticker": "ADC",
"executed_at": "2026-07-21T14:06:59.264000Z",
"size": 884.0,
"price": 80.025,
"premium": 70742.1,
"volume": 884.0,
"trade_code": " "
},
{
"ticker": "ADC",
"executed_at": "2026-07-21T14:15:02.952000Z",
"size": 400.0,
"price": 80.09,
"premium": 32036.0,
"volume": 400.0,
"trade_code": " "
},
{
"ticker": "ADC",
"executed_at": "2026-07-21T14:15:02.951000Z",
"size": 400.0,
"price": 80.09,
"premium": 32036.0,
"volume": 400.0,
"trade_code": " "
},
{
"ticker": "ADC",
"executed_at": "2026-07-21T14:09:11.848000Z",
"size": 400.0,
"price": 80.17,
"premium": 32068.0,
"volume": 400.0,
"trade_code": " "
},
{
"ticker": "ADC",
"executed_at": "2026-07-21T14:15:52.353000Z",
"size": 300.0,
"price": 80.07,
"premium": 24020.999999999996,
"volume": 300.0,
"trade_code": " "
},
{
"ticker": "ADC",
"executed_at": "2026-07-21T14:15:09.930000Z",
"size": 300.0,
"price": 80.085,
"premium": 24025.499999999996,
"volume": 300.0,
"trade_code": " "
},
{
"ticker": "ADC",
"executed_at": "2026-07-21T14:15:03.004000Z",
"size": 300.0,
"price": 80.09,
"premium": 24027.0,
"volume": 300.0,
"trade_code": " "
},
{
"ticker": "ADC",
"executed_at": "2026-07-21T14:14:14.462000Z",
"size": 300.0,
"price": 80.105,
"premium": 24031.5,
"volume": 300.0,
"trade_code": " "
}
],
"ats": {
"symbol": "ADC",
"date": "20260720",
"ats_volume": 0,
"total_volume": 242611,
"ats_ratio": 0.0,
"ats_pct": 0.0,
"signal": "Low",
"history": [
{
"date": "20260720",
"ats_ratio": 0.0
},
{
"date": "20260717",
"ats_ratio": 0.0
},
{
"date": "20260716",
"ats_ratio": 0.0
},
{
"date": "20260715",
"ats_ratio": 0.0
},
{
"date": "20260714",
"ats_ratio": 0.0
}
]
},
"polygon_dp": {
"ticker": "ADC",
"days": [
{
"date": "2026-07-21",
"close": 80.075,
"vwap": 79.94,
"volume": 81619,
"vwap_discount_pct": -0.17
},
{
"date": "2026-07-20",
"close": 80.57,
"vwap": 80.6,
"volume": 1039871,
"vwap_discount_pct": 0.04
},
{
"date": "2026-07-17",
"close": 81.12,
"vwap": 81.01,
"volume": 875007,
"vwap_discount_pct": -0.14
},
{
"date": "2026-07-16",
"close": 80.75,
"vwap": 80.28,
"volume": 1570144,
"vwap_discount_pct": -0.59
},
{
"date": "2026-07-15",
"close": 77.64,
"vwap": 77.83,
"volume": 1109659,
"vwap_discount_pct": 0.24
}
],
"avg_vwap_discount_pct": -0.12,
"signal": "Neutral"
},
"options_flow": [],
"net_premium": {
"ticker": "ADC",
"net_call_premium": "-759.00",
"net_put_premium": "200.00",
"call_premium": "759.00",
"put_premium": "200.00",
"bullish_premium": "0",
"bearish_premium": "959.00",
"put_call_ratio": "0.33333333333333333333",
"iv_rank": "29.6945",
"implied_move_perc": "0.044000",
"gex_ratio": "0.18938743627782777264",
"gex_net_change": "948.0703",
"gex_call_delta": "105973.3359",
"gex_put_delta": "-13499.9218",
"gex_date": "2026-07-21"
},
"hot_chains": [
{
"underlying_symbol": "ADC",
"expires": "2026-09-18",
"open_interest": 0,
"option_type": "call",
"delta": 0.526657106062534,
"ask_volume": 0,
"last_price": "2.53",
"implied_volatility": "0.1895170142801094",
"gamma": 0.0606217659517458,
"avg_price": "2.5300000000000000000000000000",
"bid_volume": 3,
"nbbo_ask": "4.30",
"strike": "80",
"option_symbol": "ADC260918C00080000",
"total_premium": "759.00",
"iv": 0.2032956801216811,
"volume": 3,
"nbbo_bid": "1.10"
},
{
"underlying_symbol": "ADC",
"expires": "2026-08-21",
"open_interest": 3,
"option_type": "put",
"delta": -0.474022809100651,
"ask_volume": 1,
"last_price": "2.00",
"implied_volatility": "0.218820068431713",
"gamma": 0.0770390569846089,
"avg_price": "2.00",
"bid_volume": 0,
"nbbo_ask": "2.40",
"strike": "80",
"option_symbol": "ADC260821P00080000",
"total_premium": "200.00",
"iv": 0.2203096454748294,
"volume": 1,
"nbbo_bid": "1.75"
},
{
"underlying_symbol": "ADC",
"expires": "2026-08-21",
"open_interest": 1437,
"option_type": "call",
"delta": 0.526045780207691,
"ask_volume": 0,
"last_price": null,
"implied_volatility": null,
"gamma": 0.0708082668232883,
"avg_price": null,
"bid_volume": 0,
"nbbo_ask": null,
"strike": "80",
"option_symbol": "ADC260821C00080000",
"total_premium": "0",
"iv": 0.239693150171289,
"volume": 0,
"nbbo_bid": null
},
{
"underlying_symbol": "ADC",
"expires": "2026-08-21",
"open_interest": 551,
"option_type": "put",
"delta": -0.1872361692835574,
"ask_volume": 0,
"last_price": null,
"implied_volatility": null,
"gamma": 0.0436241535368007,
"avg_price": null,
"bid_volume": 0,
"nbbo_ask": null,
"strike": "75",
"option_symbol": "ADC260821P00075000",
"total_premium": "0",
"iv": 0.263169988228896,
"volume": 0,
"nbbo_bid": null
},
{
"underlying_symbol": "ADC",
"expires": "2026-10-16",
"open_interest": 227,
"option_type": "put",
"delta": -0.0927585571257018,
"ask_volume": 0,
"last_price": null,
"implied_volatility": null,
"gamma": 0.01233252174399273,
"avg_price": null,
"bid_volume": 0,
"nbbo_ask": null,
"strike": "65",
"option_symbol": "ADC261016P00065000",
"total_premium": "0",
"iv": 0.343994500219149,
"volume": 0,
"nbbo_bid": null
},
{
"underlying_symbol": "ADC",
"expires": "2027-01-15",
"open_interest": 83,
"option_type": "call",
"delta": 0.532484428895929,
"ask_volume": 0,
"last_price": null,
"implied_volatility": null,
"gamma": 0.0380050949317973,
"avg_price": null,
"bid_volume": 0,
"nbbo_ask": null,
"strike": "80",
"option_symbol": "ADC270115C00080000",
"total_premium": "0",
"iv": 0.1867250359871261,
"volume": 0,
"nbbo_bid": null
},
{
"underlying_symbol": "ADC",
"expires": "2026-10-16",
"open_interest": 68,
"option_type": "call",
"delta": 0.304165107253909,
"ask_volume": 0,
"last_price": null,
"implied_volatility": null,
"gamma": 0.0414501276343096,
"avg_price": null,
"bid_volume": 0,
"nbbo_ask": null,
"strike": "85",
"option_symbol": "ADC261016C00085000",
"total_premium": "0",
"iv": 0.2155731704071623,
"volume": 0,
"nbbo_bid": null
},
{
"underlying_symbol": "ADC",
"expires": "2026-10-16",
"open_interest": 56,
"option_type": "put",
"delta": -0.1651218304371959,
"ask_volume": 0,
"last_price": null,
"implied_volatility": null,
"gamma": 0.02074291508324018,
"avg_price": null,
"bid_volume": 0,
"nbbo_ask": null,
"strike": "70",
"option_symbol": "ADC261016P00070000",
"total_premium": "0",
"iv": 0.305858195694296,
"volume": 0,
"nbbo_bid": null
}
]
}
Data:
{
"vix": 16.73,
"sp500": 7572.4,
"fed_funds": 3.64,
"yield_curve_10y2y": 0.41,
"hy_spread": 2.72,
"treasury": {
"date": "2026-07-20",
"month1": 3.72,
"month2": 3.81,
"month3": 3.86,
"month6": 4,
"year1": 4.03,
"year2": 4.21,
"year3": 4.25,
"year5": 4.33,
"year7": 4.45,
"year10": 4.6,
"year20": 5.12,
"year30": 5.11
},
"events": []
}
Data:
{
"days": 47,
"patterns": [
{
"name": "VWAP Touch",
"count": 47,
"pct": 100
},
{
"name": "9 EMA Touch",
"count": 47,
"pct": 100
},
{
"name": "21 EMA Touch",
"count": 47,
"pct": 100
},
{
"name": "Woodie Pivot Touch",
"count": 46,
"pct": 98
},
{
"name": "ORB Breakout",
"count": 45,
"pct": 96
},
{
"name": "PDH/PDL Touch",
"count": 43,
"pct": 91
},
{
"name": "Open Retracement",
"count": 34,
"pct": 72
},
{
"name": "Gap Fill",
"count": 26,
"pct": 55
},
{
"name": "High Vol Open",
"count": 9,
"pct": 19
},
{
"name": "Power Hour",
"count": 7,
"pct": 15
},
{
"name": "Darvas Box",
"count": 3,
"pct": 6
}
]
}